ReviewHypertension research : official journal of the Japanese Society of Hypertension2024
Usefulness and caveats of real-world data for research on hypertension and its association with cardiovascular or renal disease in Japan.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Seasonal variation in day-to-day blood pressure variability: large-scale within-individual home blood pressure data.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Individual income and blood pressure control after antihypertensive treatment initiation accounting for regional variation: a Japanese nationwide study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Body mass index modifies cardiovascular risk across blood pressure categories, particularly among underweight adults with hypertension: a 6.3 million‑person nationwide Japanese cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Effects of individual sodium-glucose cotransporter-2 inhibitors on all-cause mortality in patients with diabetic kidney disease.Clinical and experimental nephrology · 2026Article
- Blood pressure status, JSH 2019-based control rate, and associated factors among community-dwelling adults: The NOSE study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Reply to: Blood Pressure-Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real-World Data Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- The impact of slope-adjusted visit-to-visit body mass index variability on early dementia risk prediction.International journal of obesity (2005) · 2026Article
- Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function.Diabetes, obesity & metabolism · 2026Article
- Reply to: Comment on "Regional disparities in blood pressure control after hypertension treatment initiation in Japan: a real-world data analysis".Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Current hypertension epidemiology and contemporary approaches using the "Real-World Evidence Cycle" framework.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Blood Pressure-Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real-World Data Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Regional disparities in blood pressure control after hypertension treatment initiation in Japan: a real-world data analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Visit-to-visit blood pressure variability and dementia risk after considering antihypertensive treatment: real-world data from the Japanese National Health Insurance.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Trends in heart failure prevalence in post-disaster Fukushima residents 2015-2021.Scientific reports · 2026Article
- Nonlinear association between body fat percent and type 2 diabetes risk in Japanese adults: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Understanding clinical inertia in hypertension management: clues from real-world data.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Blood pressure control and treatment status at 1 year after the first health check-up in individuals with observed referral-level blood pressure.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Delayed treatment initiation as one of the crucial factors in clinical inertia: lessons from a real-world database research.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of real-world data, collected from clinical practice rather than clinical trials, has become increasingly important for investigating real-life situations, such as treatment effects. In Japan, evidence on hypertension, cardiovascular diseases, and kidney diseases using real-world data is increasing. These studies are mainly based on "the insurer-based real-world data" collected as electronic records, including data from health check-ups and medical claims such as JMDC database, DeSC database, the Japan Health Insurance Association (JHIA) database, or National Databases of Health Insurance Claims and Specific Health Checkups (NDB). Based on the insurer-based real-world data, traditional but finely stratified associations between hypertension and cardiovascular or kidney diseases can be explored. The insurer-based real-world data are also useful for pharmacoepidemiological studies that capture the distribution and trends of drug prescriptions; combined with annual health check-up data, the effectiveness of drugs can also be examined. Despite the usefulness of insurer-based real-world data collected as electronic records from a wide range of populations, we must be cautious about several points, including issues regarding population uncertainty, the validity of cardiovascular outcomes, the accuracy of blood pressure, traceability, and biases, such as indication and immortal biases. While a large sample size is considered a strength of real-world data, we must keep in mind that it does not overcome the problem of systematic error. This review discusses the usefulness and pitfalls of insurer-based real-world data in Japan through recent examples of Japanese research on hypertension and its association with cardiovascular or kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.